

## 参考文献 (続き)

- Misra K, Jamie Huang J, Daskalakis DC, Udeagu CC. Impact of PrEP on drug resistance and acute HIV infection, New York City, 2015-2017. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2019. Seattle. Abstract 107.
- Molina JM, Cahn P, Grinsztejn, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): A phase III randomised double-blind active-controlled trial. Lancet. 2011;378:238-246.
- Monogram Biosciences. Phenosense HIV drug resistance assay. Available at: https://www.monogrambio.com/resources/phenotyping/phenosense. Accessed May 12, 2021.
- Nowicka-Sans B, Gong YF, McAuliffe B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. *Antimicrob Agents Chemother*. 2012;56:3498-3507.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. June 3, 2021. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed August 2, 2021.
- Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/PedARV\_GL.pdf. Accessed May 13, 2021.
- Parienti JJ, Fournier AL, Cotte L, et al. Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication. Open Forum Infect Dis. 2021;8(7):ofab316.
- Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013;64:7-15.
- Raymond S, Delobel P, Mavigner M, et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS. 2008;22:F11-F16.
- Rose B, Gartland M, Stewart E, et al. Reduced susceptibility to temsavir is not linked to IBA or MVC resistance. Program and abstracts of the 2021 Conference on Retroviruses and Opportunistic Infections. March 6-10, 2021. Virtual. Abstract 422.